肝细胞癌筛查与肝硬化患者生存率提高相关
基于监测、流行病学和最终结果计划-医疗保险数据库的回顾性队列研究纳入2003至2013年诊断的13714例肝细胞癌患者,评估肝硬化患者确诊前3年内接受肝细胞癌筛查的情况及其与生存的关系。结果显示51.1%的患者未接受任何筛查,仅6.8%接受持续年度筛查;持续筛查与早期肿瘤检出(比值比1.98)和校正领先时间偏倚后死亡风险降低(风险比0.76)相关。
要点
- 肝硬化患者肝细胞癌确诊前3年内,51.1%未接受任何筛查,仅6.8%接受持续年度筛查。
- 持续筛查与早期肿瘤检出相关(比值比1.98;95%CI 1.68-2.33),与校正领先时间偏倚后死亡风险降低相关(风险比0.76;95%CI 0.70-0.83)。
- 接受筛查的患者比例从2003至2006年的5.4%上升至2011至2013年的8.8%(P < .001)。
核心结论
- 在监测、流行病学和最终结果计划-医疗保险数据库分析中,肝硬化患者的肝细胞癌筛查使用不足,这导致肝脏肿瘤在较晚期才被检出且生存时间较短,但接受肝细胞癌筛查的患者比例随时间增加。
研究设计与样本
- 回顾性队列研究,纳入监测、流行病学和最终结果计划-医疗保险数据库中2003年至2013年诊断的13714例肝细胞癌患者。
- 采用互斥分类(持续筛查 vs 不持续筛查 vs 无筛查)及筛查覆盖时间比例描述肝细胞癌诊断前3年内的筛查接受情况。
- 使用多变量两部分回归模型评估筛查接受的相关因素,多变量逻辑回归评估筛查与早期肿瘤检出的关联,Cox比例风险模型评估筛查与总生存的关联并校正领先时间偏倚和长度时间偏倚。
主要发现
- 大多数肝硬化患者(51.1%)在肝细胞癌诊断前3年内未接受任何筛查,仅6.8%接受持续年度筛查。
- 持续筛查比例从2003至2006年的5.4%增加至2011至2013年的8.8%(P < .001)。
- 平均筛查覆盖时间比例为13.4%,从2003至2006年的11.7%增加至2011至2013年的15.2%。
- 持续筛查与早期肿瘤检出相关(比值比1.98;95%CI 1.68-2.33),不持续筛查与早期肝细胞癌检出轻度增加相关(比值比1.31;95%CI 1.20-1.43)。
- 校正领先时间偏倚后,持续筛查与死亡风险降低相关(风险比0.76;95%CI 0.70-0.83),不持续筛查与死亡风险降低相关(风险比0.86;95%CI 0.83-0.90)。
关键数值与推荐
- 校正领先时间和长度时间偏倚后,持续筛查患者3年生存率为23%(95%CI 21%-25%),不持续筛查患者为19%(95%CI 19%-20%),无筛查患者为13%(95%CI 12%-14%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) screening of patients with cirrhosis is recommended by professional societies to increase detection of early stage tumors and survival, but is underused in clinical practice. METHODS: We conducted a retrospective cohort study of 13,714 patients diagnosed with HCC from 2003 through 2013 included in the Surveillance, Epidemiology, and End Results Program-Medicare database. We characterized receipt of HCC screening in the 3 years before HCC diagnosis using mutually exclusive categories (consistent vs inconsistent vs no screening) and the proportion of time covered with screening. Correlates for screening receipt were assessed using a multivariable 2-part regression model. We examined the association between screening receipt and early detection of tumors using multivariable logistic regression. We evaluated associations between screening receipt and overall survival using a Cox proportional hazards model, after adjustments for effects of lead-time bias and length-time bias on survival rate estimators. RESULTS: Most patients with cirrhosis (51.1%) did not receive any screening in the 3 years before a diagnosis of HCC, and only 6.8% of patients underwent consistent annual screening. The proportion with consistent screening increased from 5.4% in 2003 to 2006 to 8.8% in 2011 to 2013 (P < .001). The mean proportion of time covered was 13.4% overall, which increased from 11.7% in 2003 to 2006 to 15.2% in 2011 to 2013. Receipt of consistent screening was associated with detection of early stage tumors (odds ratio, 1.98; 95% CI, 1.68-2.33) and a reduced risk of death after correction for lead-time bias (hazard ratio, 0.76; 95% CI, 0.70-0.83). Inconsistent screening was associated with a slightly smaller increase in early detection of HCC (odds ratio, 1.31; 95% CI, 1.20-1.43) and a reduced risk of death (hazard ratio, 0.86; 95% CI, 0.83-0.90). After correction for lead- and length-time biases, higher proportions of patients with consistent (23%; 95% CI, 21%-25%) and inconsistent screening (19%; 95% CI, 19%-20%) survived for 3 years compared with patients without screening (13%; 95% CI, 12%-14%). CONCLUSIONS: In an analysis of the Surveillance, Epidemiology, and End Results Program-Medicare database, we found HCC screening to be underused for patients with cirrhosis. This contributes to detection of liver tumors at later stages and shorter times of survival. However, the proportion of patients screened for HCC has increased over time.
引用
- Choi DT, Kum HC, Park S, et al. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2018. PMID: 30616961. doi:10.1016/j.cgh.2018.10.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。